917909-56-9

Upstream product

• 10544-50-0 sulfur 
• 421-50-1 1,1,1-trifluoro-2-propanone 
• 105-56-6 ethyl 2-cyanoacetate 
• 1418113-03-7 2-amino-3-ethoxycarbonyl-4-trifluoromethyl-4,5-dihydrothiophene 
• 1094619-77-8 2-amino-4-hydroxy-4-trifluoromethyl-4,5-dihydro-thiophene-3-carboxylic acid ethyl ester 

Downstream Products

• 1094619-78-9 2-(2-methoxy-benzoylamino)-4-trifluoromethyl-thiophene-3-carboxylic acid ethyl ester 
• 1094619-27-8 2-(2-hydroxy-phenyl )-5-trifiuoromethyl-3-phenethyl-3H-thieno[2,3-d]pyrimidin-4-one 
• 1313904-79-8 C₁₇H₁₆F₃NO₄S 

Relevant academic research and scientific papers

A practical synthesis and applications of (E)-diphenyl-β- (trifluoromethyl)vinylsulfonium triflate

(E)-Diphenyl-β-(trifluoromethyl)vinylsulfonium triflate, readily prepared from 2-bromo-3,3,3-trifluoroprop-1-ene in two steps, undergoes double alkylation with active methylene compounds in dimethyl sulfoxide or ethyl acetate, in an open vessel at room te

THIENO[2,3-D]PYRIMIDIN-4(3H)-ONE, ISOXAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE AND ISOTHIAZOLO[5,4-D]PYRIMIDIN-4(5H)-ONE DERIVATIVES AS CALCIUM RECEPTOR ANTAGONISTS

The present invention is directed to novel thieno[2,3-d]pyrimidin-4(3H)-one, isoxazolo[5,4-d]pyrimidin-4(5H)-one and isothiazolo[5,4-d]pyrimidin-4(5H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula (I), wherein the variables R1, R2, R3, X and Z are as described herein. Also provided are pharmaceutical compositions comprising the compounds of formula I as well as methods of treatment employing compounds of formula I to treat a disease or disorder characterized by abnormal bone or mineral homeostasis such as hypoparathyroidism, osteoporosis, osteopenia, periodontal disease, Paget's disease, bone fracture, osteoarthritis, rheumatoid arthritis, and humoral hypercalcemia of malignancy.

THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS

The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.